Items where authors include "Cook, G"
Up a levelArticle
Ludwig, H L, Terpos, E, van de Donk, N et al. (26 more authors) (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. The Lancet Oncology, 24 (6). e255-e269. ISSN 1470-2045
Brownlie, RJ, Kennedy, R, Wilson, EB et al. (18 more authors) (2023) Cytokine receptor IL27RA is an NF-kB-responsive gene involved in CD38 upregulation in multiple myeloma. Blood Advances. ISSN 2473-9529
Thompson, MA, Boccadoro, M, Leleu, X et al. (26 more authors) (2023) Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia, 23 (3). e171-e181. ISSN 2152-2650
Smith, L orcid.org/0000-0002-4280-6323, Carmichael, J, Cook, G orcid.org/0000-0001-7196-7364 et al. (2 more authors) (2023) Development and Internal Validation of a Risk Prediction Model to Identify Myeloma Based on Routine Blood Tests: A Case-Control Study. Cancers, 15 (3). 975. ISSN 2072-6694
Behrens, J, Gaskin, G, Iggo, N et al. (7 more authors) (2023) What can we do about patients presenting with myeloma and severe renal failure? Observations from the UK MERIT plasma exchange trial. eJHaem, 4 (1). pp. 246-250. ISSN 2688-6146
Panopoulou, A, Cairns, DA orcid.org/0000-0002-2338-0179, Holroyd, AE et al. (13 more authors) (2022) Optimizing the value of lenalidomide maintenance by genetic profiling - an analysis of 556 Myeloma XI trial patients. Blood. ISSN 0006-4971
Keir, HR, Long, MB, Abo-Leyah, H et al. (192 more authors) (2022) Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. The Lancet Respiratory Medicine, 10 (12). pp. 1119-1128. ISSN 2213-2600
Shahin, M, Pawlyn, C, Weinhold, N et al. (14 more authors) (2022) The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma. Blood, 140 (Supplement 1). pp. 4232-4233. ISSN 0006-4971
Cook, G orcid.org/0000-0001-7196-7364, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (1 more author) (2022) Defining FiTNEss for treatment for multiple myeloma. The Lancet Healthy Longevity, 3 (11). e729-e730. ISSN 2666-7568
Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055
D'Agostino, M, Cairns, DA orcid.org/0000-0002-2338-0179, Lahuerta, JJ et al. (28 more authors) (2022) Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 40 (29). pp. 3406-3420. ISSN 0732-183X
Snowden, JA, Ahmedzai, SH, Cox, A et al. (10 more authors) (2022) Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation, 57 (10). pp. 1507-1513. ISSN 0268-3369
Smith, L orcid.org/0000-0002-4280-6323, Carmichael, J, Cook, G orcid.org/0000-0001-7196-7364 et al. (2 more authors) (2022) Diagnosing myeloma in general practice: how might earlier diagnosis be achieved? British Journal of General Practice, 72 (723). pp. 462-463. ISSN 0960-1643
de Tute, RM, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (14 more authors) (2022) Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 40 (25). pp. 2889-2900. ISSN 0732-183X
Dimopoulos, MA, Moreau, P, Terpos, E et al. (14 more authors) (2022) Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. Annals of Oncology, 33 (9). p. 988. ISSN 0923-7534
Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055
Ramasamy, K, Sadler, R, Jeans, S et al. (17 more authors) (2022) Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response. British Journal of Haematology, 197 (3). pp. 293-301. ISSN 0007-1048
Hough, RE, Lopes, A, Patrick, P et al. (14 more authors) (2022) Primary graft failure, but not relapse, may be identified by early chimerism following double cord unit transplantation. Blood Advances, 6 (7). pp. 2414-2426. ISSN 2473-9529
Caro, J, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 22 (4). E279-E284. ISSN 2152-2650
Auner, HW, Brown, SR orcid.org/0000-0002-7975-7537, Walker, K et al. (9 more authors) (2022) Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood Cancer Journal, 12 (4). 52. ISSN 2044-5385
Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736
Booth, S, Curley, HM, Varnai, C et al. (33 more authors) (2022) Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. British Journal of Haematology, 196 (4). pp. 892-901. ISSN 0007-1048
San-Miguel, JF, Avet-Loiseau, H, Paiva, B et al. (24 more authors) (2022) Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE. Blood, 139 (4). pp. 492-501. ISSN 0006-4971
Dimopoulos, MA, Moreau, P, Terpos, E et al. (15 more authors) (2022) Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: [Ann Oncol 2021; 32(3): 309-322]. Annals of Oncology, 33 (1). p. 117. ISSN 0923-7534
Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 107 (1). pp. 231-242. ISSN 0390-6078
Ramasamy, K, Sadler, R, Jeans, S et al. (15 more authors) (2022) COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma. British Journal of Haematology, 196 (1). pp. 95-98. ISSN 0007-1048
Giles, HV, Cook, MA, Drayson, MT et al. (12 more authors) (2021) Redefining Non-measurable Multiple Myeloma Using Mass Spectrometry. Blood. ISSN 0006-4971
Ludwig, H, Sonneveld, P, Facon, T et al. (33 more authors) (2021) COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. The Lancet Haematology, 8 (12). e934-e946. ISSN 2352-3026
Bird, S, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (12 more authors) (2021) Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical Lymphoma Myeloma and Leukemia, 21 (10). pp. 667-675. ISSN 2152-2650
Davies, F, Rifkin, R, Costello, C et al. (24 more authors) (2021) Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology, 100 (9). pp. 2325-2337. ISSN 0939-5555
Croft, J, Ellis, S, Sherborne, AL et al. (19 more authors) (2021) Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 35 (7). pp. 2043-2053. ISSN 0887-6924
Weinhold, N, Salwender, HJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (15 more authors) (2021) Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients. Haematologica. ISSN 0390-6078
Cook, G orcid.org/0000-0001-7196-7364, Corso, A, Streetly, M et al. (11 more authors) (2021) Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. Oncology and Therapy, 9. pp. 139-151. ISSN 2366-1070
Weisel, K, Mateos, M-V, Gay, F et al. (6 more authors) (2021) Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia, 35 (6). pp. 1732-1744. ISSN 0887-6924
Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736
Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736
Bygrave, C, Pawlyn, C, Davies, F et al. (11 more authors) (2021) Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma. British Journal of Haematology, 193 (3). pp. 551-555. ISSN 0007-1048
Hájek, R, Minařík, J, Straub, J et al. (33 more authors) (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology. fon-2020-1225. ISSN 1479-6694
Müller, LME, Migneco, G, Scott, GB et al. (17 more authors) (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9 (3). e001803. ISSN 2051-1426
Moreau, P, Kumar, SK, San Miguel, J et al. (67 more authors) (2021) Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology, 22 (3). e105-e118. ISSN 1470-2045
Morris, TCM, Drake, MB, Kettle, PJ et al. (12 more authors) (2021) How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. Clinical hematology international, 3 (1). pp. 27-33. ISSN 2590-0048
Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British Journal of Haematology, 192 (5). bjh.16945. pp. 853-868. ISSN 0007-1048
Lamb, MJE, Smith, A, Painter, D et al. (9 more authors) (2021) Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. BMJ Open, 11 (2). e041296. ISSN 2044-6055
Terpos, E, Mikhael, J, Hajek, R et al. (13 more authors) (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 11 (2). 40. ISSN 2044-5385
Dimopoulos, MA, Moreau, P, Terpos, E et al. (14 more authors) (2021) Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 5 (2). e528. ISSN 2572-9241
Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277
Chari, A, Samur, MK, Martinez-Lopez, J et al. (22 more authors) (2020) Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood, 136 (26). pp. 3033-3040. ISSN 0006-4971
Kaufman, JL, Dimopoulos, MA, White, D et al. (26 more authors) (2020) Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer Journal, 10 (11). 111. ISSN 2044-5385
Cook, G orcid.org/0000-0003-0223-3652 and Morris, CTCM (2020) Evolution or revolution in multiple myeloma therapy and the role of the UK. British Journal of Haematology, 191 (4). pp. 542-551. ISSN 0007-1048
Shah, V, Sherborne, AL, Johnson, DC et al. (16 more authors) (2020) Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, 34. pp. 3091-3096. ISSN 0887-6924
Hoang, PH, Cornish, AJ, Sherborne, AL et al. (8 more authors) (2020) An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood Cancer Journal, 10 (10). 101. ISSN 2044-5385
Hinsley, S, Walker, K, Sherratt, D et al. (13 more authors) (2020) The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials, 21 (1). 826. 826-.
Terpos, E, Engelhardt, M, Cook, G orcid.org/0000-0001-7196-7364 et al. (15 more authors) (2020) Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 34. pp. 2000-2011. ISSN 0887-6924
Bahlis, NJ, Dimopoulos, MA, White, DJ et al. (16 more authors) (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia, 34. pp. 1875-1884. ISSN 0887-6924
Jackson, GH, Davies, FE, Pawlyn, C et al. (20 more authors) (2020) Lenalidomide Before And After ASCT For Transplant-Eligible Patients Of All Ages In The Randomized, Phase III, Myeloma XI Trial. Haematologica. haematol.2020.247130. ISSN 0390-6078
Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Pratt, G et al. (13 more authors) (2020) Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy. British Journal of Haematology. ISSN 0007-1048
Bradbury, CA, Craig, Z orcid.org/0000-0001-9930-6648, Cook, G orcid.org/0000-0003-0223-3652 et al. (14 more authors) (2020) Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials. Blood. ISSN 0006-4971
Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Kaiser, M et al. (11 more authors) (2020) The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, 34 (2). pp. 604-612. ISSN 0887-6924
Moreau, P, Sonneveld, P, Boccadoro, M et al. (13 more authors) (2019) Chimeric Antigen Receptor T-Cell Therapy For Multiple Myeloma: A Consensus Statement From The European Myeloma Network. Haematologica, 104 (12). pp. 2358-2360. ISSN 0390-6078
Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 6 (12). e616-e629. ISSN 2352-3026
Fox, TA, Horne, GA, Craddock, C et al. (6 more authors) (2019) Trial re-investment to build better research for better impact. The Lancet, 394 (10199). pp. 635-636. ISSN 0140-6736
Ahmedzai, SH, Snowden, JA, Ashcroft, AJ et al. (19 more authors) (2019) Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. Journal of Clinical Oncology, 37 (19). pp. 1617-1628. ISSN 0732-183X
Müller, LME, Holmes, M, Michael, JL et al. (20 more authors) (2019) Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Journal for ImmunoTherapy of Cancer, 7. 164. ISSN 2051-1426
Jones, JR, Weinhold, N, Ashby, C et al. (19 more authors) (2019) Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 104 (7). pp. 1440-1450. ISSN 0390-6078
Mateos, M-V, Spencer, A, Nooka, AK et al. (16 more authors) (2019) Daratumumab-Based Regimens Are Highly Effective And Well Tolerated In Relapsed Or Refractory Multiple Myeloma Regardless Of Patient Age: Subgroup Analysis Of The Phase 3 CASTOR And POLLUX Studies. Haematologica. ISSN 0390-6078
Costello, C, Davies, FE, Cook, G orcid.org/0000-0003-0223-3652 et al. (16 more authors) (2019) INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology, 15 (13). pp. 1411-1428. ISSN 1479-6694
Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology, 185 (3). pp. 573-578. ISSN 0007-1048
Cook, G, Royle, K-L, O'Connor, S et al. (20 more authors) (2019) The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. British Journal of Haematology, 185 (3). pp. 450-467. ISSN 0007-1048
Chim, CS, Kumar, SK, Orlowski, RZ et al. (7 more authors) (2019) Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia, 33 (4). pp. 1058-1059. ISSN 0887-6924
Rule, S, Cook, G orcid.org/0000-0003-0223-3652, Russell, NH et al. (9 more authors) (2019) Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. British Journal of Haematology, 184 (6). pp. 999-1005. ISSN 0007-1048
Cook, G orcid.org/0000-0003-0223-3652, Royle, K-L, Pawlyn, C et al. (10 more authors) (2019) A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematology, 6 (3). pp. 154-166. ISSN 2352-3026
Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 20 (1). pp. 57-73. ISSN 1470-2045
Shah, V, Johnson, DC, Sherborne, AL et al. (19 more authors) (2018) Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, 132 (23). pp. 2465-2469. ISSN 0006-4971
Dimopoulos, MA, San-Miguel, J, Belch, A et al. (30 more authors) (2018) Daratumumab Plus Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of POLLUX. Haematologica, 103 (12). pp. 2088-2096. ISSN 0390-6078
Chapman, MA, Sive, J, Ambrose, J et al. (27 more authors) (2018) RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood, 132 (20). pp. 2154-2165. ISSN 0006-4971
Royle, K-L, Gregory, WM orcid.org/0000-0003-2641-8416, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (8 more authors) (2018) Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. British Journal of Haematology, 182 (6). pp. 816-829. ISSN 0007-1048
Ludwig, H, Delforge, M, Facon, T et al. (29 more authors) (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 32 (7). pp. 1542-1560. ISSN 0887-6924
Schmitz, S, Maguire, Á, Morris, J et al. (11 more authors) (2018) The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. BMC Medical Research Methodology, 18. 66. ISSN 1471-2288
Winston, DJ, Mullane, KM, Cornely, OA et al. (157 more authors) (2018) Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet, 391 (10135). pp. 2116-2127. ISSN 0140-6736
Howell, DA, Hart, RI, Smith, AG et al. (4 more authors) (2018) Myeloma: Patient accounts of their pathways to diagnosis. PLOS ONE, 13 (4). e0194788. ISSN 1932-6203
Striha, A orcid.org/0000-0003-3363-8417, Ashcroft, AJ, Hockaday, A et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. p. 169. ISSN 1745-6215
Dimopoulos, MA, Kaufman, JL, White, D et al. (8 more authors) (2018) A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clinical Lymphoma Myeloma and Leukemia, 18 (3). 163-173.e6. ISSN 2152-2650
Chim, CS, Kumar, SK, Orlowski, RZ et al. (7 more authors) (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia, 32 (2). pp. 252-262. ISSN 0887-6924
Cook, G, Zweegman, S, Mateos, M-V et al. (2 more authors) (2018) A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Critical Reviews in Oncology/Hematology, 121. pp. 74-89. ISSN 1040-8428
Johnson, DC, Lenive, O, Mitchell, J et al. (14 more authors) (2017) Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, 130 (14). pp. 1639-1643. ISSN 0006-4971
Shah, V, Sherborne, AL, Walker, BA et al. (19 more authors) (2017) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1,905 trial patients. Leukemia, 32. pp. 102-110. ISSN 0887-6924
Howell, D, Smith, A, Appleton, S et al. (5 more authors) (2017) Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study. British Journal of Haematology, 177 (1). pp. 67-71. ISSN 0007-1048
Cook, G, Iacobelli, S, van Biezen, A et al. (19 more authors) (2017) High dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: A retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 102. pp. 160-167. ISSN 0390-6078
Jones, JR, Cairns, DA, Gregory, WM orcid.org/0000-0003-2641-8416 et al. (19 more authors) (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 6 (12). e506. ISSN 2044-5385
Popat, R, Brown, SR, Flanagan, L et al. (9 more authors) (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology, 3 (12). e572-e580. ISSN 2352-3026
Pawlyn, C, Kaiser, MF, Heuck, C et al. (20 more authors) (2016) The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clinical Cancer Research, 22 (23). pp. 5783-5794. ISSN 1078-0432
Maybury, B, Cook, G, Pratt, G et al. (2 more authors) (2016) Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. Biology of Blood and Marrow Transplantation, 22 (11). pp. 1926-1937. ISSN 1083-8791
Garderet, L, Cook, G, Auner, HW et al. (12 more authors) (2016) Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting. Leukemia & Lymphoma, 58 (4). pp. 797-808. ISSN 1042-8194
Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (16 more authors) (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. The Lancet Haematology, 3 (7). e340-e351.
Moreau, P, van de Donk, NWCJ, San Miguel, J et al. (17 more authors) (2016) Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016). Drugs, 76 (9). pp. 989-990. ISSN 0012-6667
Parrish, C, Morris, CTCM, Williams, CD et al. (13 more authors) (2016) Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 22 (6). pp. 1009-1016. ISSN 1083-8791
de Tute, RM, Rawstron, AC, Gregory, WM et al. (9 more authors) (2016) Minimal Residual Disease Following Autologous Stem Cell Transplant In Myeloma: Impact On Outcome Is Independent Of Induction Regimen. Haematologica, 101 (2). e69-e71. ISSN 0390-6078
Walker, BA, Boyle, EM, Wardell, CP et al. (24 more authors) (2015) Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 33 (33). pp. 3911-3920. ISSN 0732-183X
Schey, S, Brown, SR, Tillotson, A-L et al. (13 more authors) (2015) Bendamustine, thalidomide and dexamethasone combinationtherapy for relapsed/refractory myeloma patients: results ofthe MUKone randomized dose selection trial. British Journal of Haematology, 170 (3). pp. 336-348. ISSN 0007-1048
Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2015) APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications, 6. ARTN 6997.
Feyler, S, Scott, GB, Parrish, C et al. (6 more authors) (2012) Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS ONE, 7 (5). e35981. ISSN 1932-6203
McGovern, TH, Vesteinsson, O, Fridriksson, A et al. (14 more authors) (2007) Landscapes of settlement in Northern Iceland: historical ecology of human impact and climate fluctuation on the Millennial Scale. American Anthropologist, 109 (1). 27 - 51. ISSN 0002-7294
Lawson, IT, Church, MJ, Edwards, KJ et al. (2 more authors) (2007) Peat initiation in the Faroe Islands: climate change, pedogenesis, or human impact? Earth and Environmental Science Transactions of the Royal Society of Edinburgh,, 98 (1). 15 - 28. ISSN 1755-6910
Church, MJ, Arge, SV, Brewington, S et al. (9 more authors) (2005) Puffins, pigs, cod, and barley: palaeoeconomy at Undir Junkarinsfløtti, Sandoy, Faroe Islands. Environmental Archaeology, 10 (2). 179 - 197. ISSN 1461-4103
Conference or Workshop Item
Cook, G, Pawlyn, C, Royle, K-L et al. (20 more authors) (2021) Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials. In: 63rd American Society of Hematology Annual Meeting, 11-14 Dec 2021, Atlanta, Georgia, USA.
Hayden, PJ, Eikema, D-J, Koster, L et al. (21 more authors) (2020) O123: 25 Years of Autologous Transplantation for Myeloma in Ebmt Centres - Changing Practice Patterns. In: The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 Aug - 01 Sep 2020, Online.
Kaufman, JL, Usmani, SZ, San-Miguel, J et al. (16 more authors) (2020) Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). In: 61st American Society of Hematology (ASH) Annual Meeting, 07-10 Dec 2019, Orlando, Florida, USA.
McGinnis, K, Murtuza Baker, S, Berry, A et al. (6 more authors) (2018) Glucocorticoids promote DNA repair to reduce efficacy of radiotherapy in Glioblastoma. In: Society for Endocrinology BES 2018, 19-21 Nov 2018, Glasgow, UK.
Proceedings Paper
Yong, K, Royle, K-L orcid.org/0000-0003-0225-1199, Ramasamy, K et al. (23 more authors) (2022) Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation. In: Blood. 64th ASH Annual Meeting, 10-13 Dec 2022, New Orleans, Louisiana. American Society of Hematology , pp. 1844-1846.
Leslie, F, Kershaw, S, Pfänder, P et al. (6 more authors) (2019) Global phosphoproteomics links rapidly induced cytoplasmic signals to transcriptional control. In: Endocrine Abstracts (2019). Society for Endocrinology BES 2019, 11-13 Nov 2019, Brighton, UK. Society for Endocrinology .
Leif, F, Pfänder, P, Murtuza Baker, S et al. (8 more authors) (2019) Nuclear receptor profiling predicts chemical disruptors as risk factors for developing breast cancer. In: Endocrine Abstracts (2019). Society for Endocrinology BES 2019, 11-13 Nov 2019, Brighton, UK. Society for Endicronology .
McGinnis, K, Murtuza Baker, S, Donaldson, I et al. (7 more authors) (2019) Single cell RNA-seq reveals complex processing of glucocorticoid controlled transcriptional programmes. In: Endocrine Abstracts (2019). Society for Endocrinology BES 2019, 11-13 Nov 2019, Brighton, UK. Society for Endicronology .
Weisel, K, Mateos, M-V, Gay, FM et al. (6 more authors) (2018) Association between Patient Profile and Outcomes of Best Responders to Carfilzomib: A Post-Hoc Sub-Group Analysis of Aspire and Endeavor. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology , p. 3299.
Shah, V, Johnson, DC, Sherborne, AL et al. (18 more authors) (2018) Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San Diego, California, USA. American Society of Hematology , p. 2000.
Croft, J, Hall, A, Walker, K et al. (11 more authors) (2018) Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. In: Blood. ASH 2018 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology , p. 4482.
Hajek, R, Terpos, E, Lee, HC et al. (20 more authors) (2018) Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .
Cook, G orcid.org/0000-0003-0223-3652, Parrish, C, Yong, K et al. (12 more authors) (2018) Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .
Bygrave, CA, Pawlyn, C, Davies, FE et al. (19 more authors) (2018) Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .
Jackson, GH, Davies, FE, Pawlyn, C et al. (18 more authors) (2018) A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San DIego, California, USA. American Society of Hematology , p. 302.
Cook, G orcid.org/0000-0003-0223-3652, Cella, D, Chen, C et al. (6 more authors) (2018) Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .
Bahlis, N, Dimopoulos, MA, White, DJ et al. (14 more authors) (2018) Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .
Moreau, P, White, D, Benboubker, L et al. (12 more authors) (2018) Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux). In: Haematologica: the hematology journal. 1st European Myeloma Network Meeting, 19-21 Apr 2018, Turin, Italy. Ferrata Storti Foundation , p. 31.
Cook, G orcid.org/0000-0003-0223-3652 (2018) What kind of trials do we need in the future to address open issues in NDMM? Better research, better impact. In: Haematologica. 1st European Myeloma Network Meeting, 19-21 Apr 2018, Turin, Italy. Ferrata Storti Foundation , p. 4.
Sherborne, AL, Shah, V, Ellis, S et al. (15 more authors) (2017) Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. In: Blood. 59th ASH Annual Meeting and Exposition, 09-12 Dec 2017, Atlanta, GA, USA. American Society of Hematology , p. 1767.
Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2014) Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. In: BLOOD. 56th ASH Annual Meeting 2014, 06-09 Dec 2014, San Francisco, California, USA. American Society of Hematology .